Back to selected funds

Search for another investment

AXA Fram...

Price: 467.5000GBX

Change: icon-up-small 0.60%

Open an account

AXA Framlington Biotech Z Acc GBP

Fund
Search input

AXA Framlington Biotech Z Acc GBP

ISIN:

GB00B784NS11

Risk level:

FE fundinfo Rating:

4 of 5

IA Sector:

IA Specialist

Income type:

Accumulation

Price:

467.5000GBX

19 June 2025

Last change:

icon-up-small 0.60%

1 year change:

icon-down-small -11.26%

5 year annualised return:

0.60%

12 month yield:

0.00%

Disclosure Document

Key Investor Information Document (KIID)

Open an account

At a glance

At a glance performance and information

Eligibility:

Share Dealing Account

ISA

SIPP

The value of investments, and income from them, can rise and fall so you may get back less than you invest. If you are unsure about investing, seek independent advice

1 W 1 M 3 M 6 M YTD 1 Y 3 Y 5 Y Max

Add to chart:

Fund:

AXA Framlington Biotech Z Acc GBP
Sector:

IA Specialist
Benchmark:

Index

Discrete calendar year performance

Discrete calendar year performance
Investment	31/03/20 to 31/03/21	31/03/21 to 31/03/22	31/03/22 to 31/03/23	31/03/23 to 31/03/24	31/03/24 to 31/03/25
AXA Framlington Biotech Z Acc GBP	24.02%	0.66%	9.15%	10.89%	-10.42%
IA Specialist	31.15%	5.77%	-0.66%	9.19%	3.49%
N/A	N/A%	N/A%	N/A%	N/A%	N/A%

Trailing returns

(*annualised)

Trailing returns
Investment	3 months	6 months	1 year	3 years*	5 years*
AXA Framlington Biotech Z Acc GBP	-5.97%	-11.16%	-11.26%	5.26%	0.60%
IA Specialist	2.23%	5.84%	7.76%	7.73%	6.77%
N/A	N/A%	N/A%	N/A%	N/A%	N/A%

Overview

Fund Objective: The aim of this Fund is to provide long-term capital growth.

Manager name:

AXA IM UK

Manager start date:

29 March 2024

Investment style:

Growth

Region (geographical):

Global

Manager Biography:

N/A

Benchmark:

N/A

Sector:

IA Specialist

FE fundinfo Rating:

4 of 5

Fees & charges

Fees and Charges

Fees and Charges
Charge	Who receives this?	What is it?	Amount
Initial charge:	The fund manager	Charges applied by the fund management company for investing in their fund. Please note that Investment Managers may charge each time you buy new units or shares in a fund or trust. Where Investment Managers would have an entry charge, we will negotiate to have it waived so you will not be charged.	0.00%
Ongoing Charges:	The fund manager	The annual charge paid to a fund manager to cover the costs of running the fund. It is an estimate based on the actual amount charged in the previous year.	0.82%
Performance Fee:	The fund manager	A performance fee joins up the interest of the fund manager and their investors. A performance fee is taken when the fund beats pre-set conditions.	0%
Typical transaction cost:	The fund manager	The costs of dealing within a fund, which the Investment Manager must pay to continue managing the assets. This includes where the Manager decides to sell one stock and buy another. The costs will vary from one fund to another based on how often the Investment Manager trades and the costs applied when trading.	0.188%*
Dealing commission:	iWeb	The cost of buying or selling some or all of your investment.	£5.00 (per online trade)

*This is an indication based on the market average. The fund’s actual transaction cost will be shown before you place a trade.

Account charges are not included

Breakdown

Asset Allocation

Fund size: 307,087,824.19 GBX

Chart date: June 19, 2025

Top 10 Holdings

Top 10 Holdings
Security	Weight
Vertex pharmaceuticals inc	9.00%
Amgen inc.	7.39%
Astrazeneca plc	6.85%
Regeneron pharmaceuticals inc	6.76%
Gilead sciences inc	5.04%
Argenx se	3.89%
Alnylam pharmaceuticals inc	3.73%
Insmed inc ord	3.40%
Neurocrine biosciences inc	2.87%
Verona pharma plc	2.65%

Sectors

Sectors
Sectors	Weight
Biotechnology/Medical	83.50%
Pharmaceuticals	15.45%
Money Market	1.05%

World regions

World regions
Country	Weight
North America	73.71%
UK	11.78%
Europe Ex UK	11.40%
Emerging	2.06%
Cash	1.05%

ESG

What is ESG?

ESG stands for Environmental, Social and Governance and is an approach for evaluating to what extent a company works towards social goals. For investors this can be used in order to understand how their funds and the assets they are made up of work towards these goals and use that information to help make sustainable investment choices.

This product uses terms and/or marketing related to sustainability. It does not have a label, but the manager is required to produce a disclosures document.

The FCA website sets out further information in relation to the sustainability labelling and disclosure requirements.

Disclosure Document

Important legal information

The IWeb Share Dealing Service is operated by Halifax Share Dealing Limited. Halifax Share Dealing Limited. Registered in England and Wales no. 3195646. Registered Office: Trinity Road, Halifax, West Yorkshire, HX1 2RG. Authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under registration number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

The data provided on the website by Broadridge is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. Broadridge makes no assurances or warranties, expressed or implied, as to the accuracy, timeliness, fitness for purpose or availability of the mechanisms by which we receive, store and/or distribute the data. Any views and opinions made on this website do not represent those of Broadridge.